MAVERICC (Marker Evaluation for Avastin Research in CRC): A Randomized Phase II Study of Bevacizumab+mFOLFOX6 Vs. Bevacizumab+FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2016
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms MAVERICC
- Sponsors Genentech
- 07 Jun 2017 Biomarkers information updated
- 11 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 15 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.